Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADRCs for Facet Joint Osteoarthritis
NCT03513731Recruiting
- Sponsor
- InGeneron
- Start
- Dec 2018
- Primary completion
- Dec 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Randomised, single-blind trial of autologous adipose-derived stem/stromal cells in facet joint osteoarthritis (2 arms), sponsored by InGeneron. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 52 weeks. Started Dec 2018; status: recruiting.
02
Drugs
autologous adipose-derived stem/stromal cells
03
Conditions
facet joint osteoarthritis
Beyond the preview
Go deeper on NCT03513731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03513731.